Catabasis Names Angelika Fretzen, Ph.D., Vice President of Development

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc., a clinical stage drug development company built on a pathway pharmacology technology platform, today announced that it has named Angelika Fretzen, Ph.D., as vice president of development. Dr. Fretzen brings to Catabasis 14 years of entrepreneurial drug discovery and development experience.

"Angelika brings valuable drug development experience, in all phases from discovery through commercialization and life cycle management"
"Angelika brings valuable drug development experience, in all phases from discovery through commercialization and life cycle management," said Michael Jirousek, Ph.D., co-founder and chief scientific officer of Catabasis. "We look forward to leveraging her capabilities as we progress our CAT-2003 and CAT-1004 programs through Phase 2 development and advance CAT-2054 and additional programs into the clinic."

Prior to joining Catabasis, Dr. Fretzen was vice president of pharmaceutical chemistry and development at Ironwood Pharmaceuticals. She led pharmaceutical development and CMC related aspects of Ironwood's linaclotide program through its approval as Linzess® in the US and as ConstellaTM in Canada and Europe. Dr. Fretzen has been responsible for discovery and development programs for small molecules and peptides in a variety of different disease areas. Prior to joining Ironwood Pharmaceuticals, Dr. Fretzen was an Alexander von Humboldt Fellow in the Department of Chemistry and Chemical Biology at Harvard University. She holds a Diplom (M.S.) in chemistry from the University of Würzburg in Germany and her Ph.D. in organic chemistry from the University of Geneva, Switzerland. Dr. Fretzen also holds an MBA from Suffolk University in Boston.

About Catabasis

Catabasis Pharmaceuticals is leveraging its pathway pharmacology drug development platform to bring important medicines to patients with severe lipid disorders and rare diseases. The Company's mission is to address difficult-to-treat diseases through the simultaneous modulation of multiple targets in a disease pathway. For more information on our technology and pipeline of drug candidates, please visit


Corporate and Media Contact
Catabasis Pharmaceuticals Inc.
Andrea Matthews, T: 617-349-1971
[email protected]

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.